ArticleEndocrine connections2026
Increased mortality in chronic hypoparathyroidism: a nationwide cohort study in Sweden.
Article in Endocrine connections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPrevious studies on mortality outcomes in patients with chronic hypoparathyroidism have reported inconsistent results.
objectiveTo assess all-cause and cause-specific mortality and estimate the prevalence of chronic hypoparathyroidism in Sweden.
methodsChronic hypoparathyroidism was defined as the combination of ICD-10 diagnoses and long-term dispensations of active vitamin D. Nationwide diagnostic codes, drug dispensation, and mortality data were obtained from the National Patient Register, Prescribed Drugs Register, Cause of Death Register, and the Total Population Register. Mortality was compared between groups using Cox proportional hazards models, adjusting for age and baseline comorbidities.
resultsWe identified 1,982 individuals with chronic hypoparathyroidism between 1997 and 2018, yielding a minimum prevalence of 19.4 per 100,000 inhabitants. We randomly selected 19,820 controls matched by age, sex, and county of residence.After excluding individuals with baseline thyroid cancer and their controls, 1,825 patients and 17,922 controls remained. Patients had higher all-cause mortality than controls (HR: 1.55; 95% CI: 1.40-1.72). Mortality was higher in patients with nonsurgical (HR: 2.16, 95% CI: 1.76-2.65) than postsurgical hypoparathyroidism (HR: 1.39, 95% CI: 1.23-1.58). The strongest associations were observed for endocrine, nutritional, and metabolic disorders (HR: 6.46, 95% CI: 2.43-17.21), followed by infectious diseases (HR: 3.53, 95% CI: 2.07-6.04), genitourinary diseases (HR: 2.40, 95% CI: 1.33-4.33), respiratory diseases (HR: 1.67, 95% CI: 1.23-2.28), and circulatory diseases (HR: 1.47, 95% CI: 1.23-1.77).
conclusionPatients with chronic hypoparathyroidism have an elevated risk of all-cause mortality, particularly those with nonsurgical disease. These findings highlight the clinical burden of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.